Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
Audreylie Lemelin(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Ashley Holub(Analysis Group (United States)), Lynn Huynh(Northern Arizona University), Naveen S. Basappa, Louise Clear(Analysis Group (United States)), Connor Wells(Queen Mary University of London), Vishal Navani(Hunter Medical Research Institute), Matthew Scott Ernst(University of Calgary), Shirley Wong(Western Hospital), Bradley A. McGregor(Harvard University), Jae‐Lyun Lee(Ulsan College), Mei Sheng Duh(Analysis Group (United States)), Sumanta Pal(City of Hope), Takeshi Yuasa(Japanese Foundation For Cancer Research), Haoran Li(General Hospital of Shenyang Military Region), Catherine Nguyen(Inserm), Rose Chang(Analysis Group (United States)), Frede Donskov(Aarhus University Hospital), Anil Kapoor(People’s University)
Cited by 0
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|Cancer Cell|2021|624
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
|Cancer Cell|2021|528